OncoMatch/Clinical Trials/NCT07202364
A Study of YL202 in Patients With Advanced Solid Tumors
Is NCT07202364 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies YL202 for non small cell lung cancer.
Treatment: YL202 — This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Cervical Cancer
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: HER3-targeted therapy
Prior drug therapy targeting HER3
Cannot have received: topoisomerase I inhibitor
Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors
Cannot have received: allogeneic bone marrow transplantation
Prior treatment with allogeneic bone marrow transplantation
Cannot have received: solid organ transplantation
Prior treatment with ... solid organ transplantation
Lab requirements
Blood counts
The function of organs and bone marrow meets the requirements within 7 days prior to the first dose
Kidney function
The function of organs and bone marrow meets the requirements within 7 days prior to the first dose
Liver function
The function of organs and bone marrow meets the requirements within 7 days prior to the first dose
The function of organs and bone marrow meets the requirements within 7 days prior to the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07202364 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior HER3-targeted therapy, topoisomerase I inhibitor, allogeneic bone marrow transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify